On course to publish our scientific research and findings.
We are committed to publishing the results from our pre-clinical and clinical research in collaboration with the scientists, physicians, researchers and others with whom we collaborate at medical meetings and in peer-reviewed publications.
| Date | Type | Description | Link |
|---|---|---|---|
| Dec 2023 | Journal Papers | Hurrish, et. al., Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro. Biochem Pharmacol. 2023 Dec 9:115981. |
https://www.sciencedirect.com/science/article/abs/pii/S0006295223005749?via%3Dihub |
| Dec 2023 | Poster | A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML) |
/images/ASH_2023_Voruciclib_Poster_Final.pdf |
| Dec 2021 | Poster | A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML, 63rd ASH Annual Meeting, December 2021 |
/sites/meipharma-corp/files/mei-pharma/pipeline/publications/ash-2021-vorucicli… |
| Apr 2021 | Poster | Voruciclib, a CDK9 inhibitor, downregulates MYC and inhibits proliferation of KRAS mutant cancers in preclinical models, AACR Annual Meeting 2021 |
/sites/meipharma-corp/files/mei-pharma/pipeline/publications/voruciclib-poster… |
| Feb 2020 | Journal Papers | Luedtke, et al. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia. Signal Transduct Target Ther. 2020 Feb 26;5(1):17. |
https://pubmed.ncbi.nlm.nih.gov/32296028/ |
| Dec 2018 | Poster | Voruciclib, an Oral, Selective CDK9 Inhibitor, Enhances Cell Death Induced by the Bcl-2 Selective Inhibitor Venetoclax in Acute Myeloid Leukemia |
/sites/meipharma-corp/files/mei-pharma/media/ash2018-voruciclib-luedtke.pdf |
| Dec 2017 | Journal Papers | Dey, et al. Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition. Sci Rep. 2017 Dec 21;7(1):18007. |
https://www.nature.com/articles/s41598-017-18368-w |
| Jul 2016 | Journal Papers | Eliades, et al. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biol Ther. 2016 Jul 2;17(7):778-84. |
https://pubmed.ncbi.nlm.nih.gov/26810603/ |
| Apr 2016 | Poster | Voruciclib, a clinical stage CDK inhibitor sensitizes triple negative breast cancer xenografts to proteasome inhibition. AACR Annual Meeting, April 2016 |
/sites/meipharma-corp/files/mei-pharma/media/voruciclib-aacr-2016.pdf |
| Nov 2015 | Journal Papers | Paiva, et al. Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells. PLoS One. 2015 Nov 25;10(11) |
https://pubmed.ncbi.nlm.nih.gov/26606677/ |
| Jun 2015 | Poster | Phase I trial of the CDK 4/6 inhibitor, P1446A-05 (voruciclib) in combination with the BRAF inhibitor (BRAFi), vemurafenib in advanced, BRAF-mutant melanoma. ASCO Annual Meeting, June 2015 |
/sites/meipharma-corp/files/mei-pharma/media/voruciclib-braf-combo-asco-2015.pdf |